Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer

(2015) V. K. Anagnostou et al.   CLINICAL CANCER RESEARCH

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

(2014) Raju R Raval et al.   Journal for ImmunoTherapy of Cancer

Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?

(2013) Theresa L. Whiteside   CANCER IMMUNOLOGY IMMUNOTHERAPY

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

The use of endogenous T cells for adoptive transfer

(2013) Cassian Yee   IMMUNOLOGICAL REVIEWS

Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

(2013) Christine Pasero et al.   IMMUNOLOGY LETTERS

TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells

(2013) Yoshikane Kikushige et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Cancer Immunotherapy Comes of Age

(2011) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

(2010) Li Yang et al.   TRENDS IN IMMUNOLOGY

CTLA-4: a key protein in autoimmunity

(2009) Jagadeesh Bayry   Nature Reviews Rheumatology

About human tumor antigens to be used in immunotherapy

(2008) S. Lucas et al.   SEMINARS IN IMMUNOLOGY